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Abstract 
 
In health technology assessment, decisions are based on complex cost-effectiveness models 
which, to be implemented, require numerous input parameters. When some of the relevant 
estimates are not available the model may have to be simplified. Multi-parameter evidence 
synthesis allows to combine data from diverse sources of evidence resulting in obtaining 
estimates required in clinical decision-making that otherwise may not be available.  We 
demonstrate how bivariate meta-analysis can be used to predict unreported estimate of a 
treatment effect enabling implementation of multi-state Markov model, which otherwise needs 
to be simplified. To illustrate this, we used an example of cost-effectiveness analysis for 
docetaxel in combination with prednisolone in metastatic hormone-refractory prostate cancer 
(mHRPC). Bivariate meta-analysis was used to model jointly available data on treatment 
effects on overall survival (OS) and progression-free survival (PFS) to predict the unreported 
effect on PFS in a study evaluating docetaxel with prednisolone. Predicted treatment effect on 
PFS allowed implementation of a three-state Markov model comprising of stable disease, 
progressive disease and death states, whilst lack of the estimate restricted the model to two-
state model (with stable disease and death states). The two-state and three-state models were 
compared by calculating the incremental cost-effectiveness ratios, which was much lower in 
the three-state model: £21966 per QALY gained compared to £30026 obtained from the two-
state model. In contrast to the two-state model, the three-state model has the advantage of 
distinguishing patients who progressed from those who did not progress. Hence the use of 
advanced meta-analytic technique helped to obtain relevant parameter estimate to populate 
a model which describes natural history more accurately, and at the same helped to prevent 
valuable clinical data from being discarded.   
 
 
 
1 Introduction 
In health technology assessment (HTA), reimbursement decisions for new health technologies 
are made based on cost-effectiveness models. Such, often complex, models are implemented 
using estimates of effectiveness, health related quality of life (HRQoL) and cost. Effectiveness 
estimates are usually obtained from the systematic literature review and meta-analysis of 
randomised controlled trials (RCTs) which are designed to give an estimate of the treatment 
effect on the primary clinical outcome. The choice of the outcome measures for RCTs and 
reporting of findings rarely takes into consideration what is important from the HTA perspective 
and therefore trials not always report all outcomes relevant to the HTA. There is often a lot of 
heterogeneity in reporting of clinical outcomes due to, for example, variety of scales on which 
effectiveness can be measured, different time points at which different studies report their 
outcomes or different control arms. Relevant outcomes may not be reported due to poor study 
design, outcome reporting bias or some problems with outcome measurement. This may lead 
to difficulties with populating cost-effectiveness model with appropriate parameters. 
 
Bayesian statistics provides flexible framework for modelling complex data structures by 
allowing multiple parameters to be modelled simultaneously. This is particularly useful when 
multiple data sources need to be brought together, which can be achieved by the use of multi-
parameter evidence synthesis. Network meta-analysis (NMA) facilitates simultaneous 
comparison of multiple treatment options with an aim to obtain effectiveness estimates for all 
possible treatment contrasts including those that may not be directly reported by any RCTs1.  
Multivariate meta-analysis allows to model jointly treatment effects on multiple outcomes with 
the aim of obtaining poled effect on all the outcomes while taking into account of the correlation 
between them2-4. There are many advantages of multivariate meta-analysis, including (i) 
potentially increased precision of effectiveness estimates which can lead to increased 
precision of other estimates required in decision modelling, such as HRQoL5,(ii)  inclusion of 
all relevant evidence from studies reporting relevant outcomes (other than the main outcome 
of interest) preventing valuable data from being discarded and (iii) potentially reduced outcome 
reporting bias6. In this paper, we propose the use of bivariate meta-analysis for purpose of 
predicting unreported treatment effects in individual studies, rather than obtaining overall 
pooled effects4, 7, 8, for purpose of informing a complex HTA modelling framework.  
 
A multi-state Markov model is one of the most frequently used decision models in HTA. The 
number of health states in the model depends on the specific disease area and the states 
should be chosen to represent important events (clinically and economically) and be mutually 
exclusive such as, for example, three-state model including asymptotic (or stable disease) 
state, progressive disease state and death9. To populate a three state the model in cancer, 
the transition probabilities between the states are obtained from data on both overall survival 
(OS) and progression free survival (PFS). When data are not available to estimate all 
parameters of the model, such model may need to be simplified which conflicts with its 
purpose to simulate real life scenarios. We illustrate how multi-parameter evidence synthesis 
can be used to fully utilize the available evidence to inform parameters of Markov model. 
 
To demonstrate this methodology, we apply the methods to inform cost-effectiveness analysis 
of docetaxel in prostate cancer. In the technology assessment of docetaxel, Collins et al. 
constructed a two-state Markov model consisting of stable disease and death states10. 
Reviewing the evidence on effectiveness of docetaxel made it apparent that relevant evidence 
on the treatment effect on progression was not available at the submission stage of evidence 
for docetaxel, limiting the development of the decision model to the two states only. We will 
demonstrate how the use of multivariate meta-analysis can lead to obtaining relevant 
estimates necessary to populate the three-state Markov model including a progression state. 
 
 2. Methods 
 
2.1 Motivating example and sources of evidence  
In 2007 the National Institute for Health and Care Excellence (NICE) carried out a technology 
appraisal of use of docetaxel in combination with either prednisone or prednisolone (D+P) as 
treatments for metastatic hormone-refractory prostate cancer (mHRPC)10. The technology 
appraisal aimed to evaluate the clinical- and cost-effectiveness of the combination therapy. 
Evidence base for the meta-analysis in this HTA included four studies which investigated 
interventions that were licensed at the time of the HTA submission, namely D+P, mitoxantrone 
plus prednisone (M+P), prednisolone alone (P), mitoxantrone plus hydrocortisone (M+H) and 
hydrocortisone alone (H). Data from the four RCTs11-14, listed in Table 1, are included in our 
example and referred to as HTA set.  None of the studies reported the effect of docetaxel on 
PFS, required to populate three-state Markov model for the cost-effectiveness assessment of 
this treatment and only one trial reported the effect of docetaxel on OS (TAX 32713). The details 
of the systematic review conducted by Collins et al10 are included in the Appendix A of 
Supplementary Materials, which also includes set of studies of unlicensed treatments used to 
inform some of the model parameters in this paper. 
 
 
 
Table 1: Randomised controlled trials in HTA report base clinical-effectiveness analysis 
Trial Year 
No. 
of arms 
Reference 
Treatment 
Comparative 
Treatment(s) 
Total no. 
of patients 
OS 
data 
PFS 
data 
        
CCI-NOV2214 1996 2 M+P P 161 Yes Yes 
        
CALGB 918212 1999 2 M+H H 242 Yes Yes 
        
Berry et al.11 2002 2 M+P P 120 Yes Yes 
        
TAX 32713 
2004 
3 M+P 
D+P  
1006 Yes No  D1+P 
                
 
 
2.2 Methods of evidence synthesis for predicting treatment effect on PFS for docetaxel  
Figure 1 shows a schematic diagram of the procedures for the prediction of PFS hazard ratio 
(HR) of D+P versus M+P as well as the use of indirect comparisons to obtain the estimates of 
both PFS and OS HRs for D+P versus P. For purpose of conducting indirect comparisons 
meta-analysis, we group both corticosteroids P and H denoting them as P.  The components 
of the analysis were conducted in the following order:  
1. To unify the scale of the treatment effects across studies, Kaplan-Meier curves for OS and 
PFS were used, where available, to reconstruct the individual patient data (IPD) for the 
four RCTs.  
2. Treatment effects on log HR scale were estimated by performing survival analysis on the 
reconstructed IPD.  
3. A bivariate meta-analytic model was used to model jointly log HRs on PFS and OS 
resulting in predicted estimate of the log HR on PFS for trial TAX 327 (that compared 
interventions: D+P to M+P) which was not reported.  
4. The predicted log HR on PFS for trial TAX 327 was then used in a random-effect indirect 
comparison meta-analysis (ICMA) (also conducted for OS analysis in the HTA report) to 
obtain the estimate of the effect of D+P versus P on PFS. 
Methods for obtaining the summary trial data for this analysis on appropriate scale are 
described in Section 2.2.1. Meta-analytic method for combining evidence on both PFS and 
OS for purpose of predictions is described in section 2.2.2, whilst section 2.2.3 discusses 
briefly ICMA. 
 
 
 Figure 1: Diagram for the clinical effectiveness analysis using BRMA 
 
2.2.1 Data extraction and reconstruction 
For the purpose of evidence synthesis, summary data on effectiveness measured on OS and 
PFS were analysed on the log HR scale, to allow for assumption of normality of the effect 
estimates. To obtain the estimates on this scale, IPD on OS and PFS for each of the RCTs 
were reconstructed from their respective Kaplan-Meier survival curves, if reported, using the 
method proposed by Guyot and colleagues15. Reconstructed IPD allow log HRs and 
corresponding standard errors (SEs) to be estimated using survival analysis instead of crude 
estimation using median survival times and log-rank test p-values reported in the RCTs. 
Survival analyses, using Cox model, were performed on the reconstructed IPD of the four 
RCTs in the HTA Set for OS and two in the HTA Set for PFS RCTs (only CALGB918212 and 
Berry11 reported Kaplan-Meier survival curves for PFS) to estimate the log HRs for the meta-
analysis.  The estimate of log HR on PFS for trial CCI-NOV2213 was obtained from the HTA 
report10 as it was not reported in the published article. Trial TAX 327 did not report PFS 
endpoint.  
 
2.2.2 Bivariate meta-analysis 
Bivariate random-effects meta-analysis (BRMA) was used for purpose of predicting the 
treatment effect on PFS in the docetaxel study (TAX 327) by modelling treatment effects 
measured by log HRs on OS and PFS jointly, taking into account of the correlation between 
them. 
In this model, 𝑌𝑂𝑆 and 𝑌𝑃𝐹𝑆, the treatment effect on OS and PFS on log HR scale, are 
assumed to be normally distributed and correlated  
 (
𝑌𝑂𝑆,𝑖
𝑌𝑃𝐹𝑆,𝑖
) ~ 𝑁𝑜𝑟𝑚𝑎𝑙 ((
𝜇𝑂𝑆,𝑖
𝜇𝑃𝐹𝑆,𝑖
) , Σ𝑖) (1) 
with the within-study  variance-covariance matrices Σ𝑖 = (
𝜎𝑂𝑆,𝑖
2 𝜎𝑂𝑆,𝑖𝜎𝑃𝐹𝑆,𝑖𝜌𝑤,𝑖
𝜎𝑃𝐹𝑆,𝑖𝜎𝑂𝑆,𝑖𝜌𝑤,𝑖 𝜎𝑃𝐹𝑆,𝑖
2 ) 
comprising of the within-study standard errors of the estimates, 𝜎𝑂𝑆,𝑖 and 𝜎𝑃𝐹𝑆,𝑖, and the within-
study correlation 𝜌𝑤,𝑖 between the estimates in each study 𝑖. The treatment effects 𝑌𝑂𝑆,𝑖 
and 𝑌𝑃𝐹𝑆,𝑖 are the estimates the true effects, 𝜇𝑂𝑆,𝑖 and 𝜇𝑃𝐹𝑆,𝑖, which are also correlated and can 
be modelled in the form of the product of univariate conditional normal distributions, the 
product normal formulation4, 7, 8: 
 𝜇OS,𝑖~𝑁𝑜𝑟𝑚𝑎𝑙(𝜂OS, 𝜓OS
2 ) 
𝜇PFS,𝑖|𝜇OS,𝑖 ~ 𝑁𝑜𝑟𝑚𝑎𝑙(𝜂PFS,𝑖, 𝜓PFS
2 ) 
 
 𝜂PFS,𝑖 =  𝜆0 + 𝜆1(𝜇OS,𝑖 − 𝜇OS,𝑖̅̅ ̅̅ ̅̅ ) (2) 
where 𝜓OS
2  is equal to the between-studies variance 𝜏OS
2  (heterogeneity parameter) of the 
treatment effects on OS,  𝜓PFS
2  is the conditional between-studies variance of the treatment 
effects on PFS conditional on the effect on OS, which relates to the heterogeneity parameter 
𝜏PFS
2 ; 𝜓PFS
2 = 𝜏PFS
2 − 𝜆1
2𝜏OS
2 . The slope 𝜆1 = 𝜌𝑏𝜏𝑃𝐹𝑆/𝜏𝑂𝑆 and 𝜌𝑏 is the between-studies 
correlation. Prior distributions are placed on the between-studies parameters, for example 
uniform distribution for the correlation 𝜌𝑏 ~ 𝑈𝑛𝑖𝑓𝑜𝑟𝑚(−1, 1) and half normal distributions for 
the standard deviations; 𝜏OS,𝑖 ~ 𝐻𝑁𝑜𝑟𝑚𝑎𝑙(0, 10
3) and 𝜏PFS,𝑖 ~ 𝐻𝑁𝑜𝑟𝑚𝑎𝑙(0, 10
3), which give 
implied prior distributions on 𝜆1, 𝜓𝑂𝑆 and  𝜓𝑃𝐹𝑆 obtained using the above relationships between 
the parameters. Prior distributions are also placed on other unknown parameters, the intercept 
𝜆0~𝑁𝑜𝑟𝑚𝑎𝑙(0, 10
3) and the within-study correlations 𝜌𝑤,𝑖 ~ 𝑈𝑛𝑖𝑓𝑜𝑟𝑚(−1, 1). The pooled 
treatment effects are 𝐻𝑅OS =  exp (𝜂OS) and 𝐻𝑅PFS =  exp (𝜆0). Further assumption about 
exchangeability of population variances4 were made in order to predict the standard error 
corresponding to the missing HR on PFS, comparing D+P versus M+P, in TAX 327.  
The missing, unreported effect on PFS in TAX 327 trial is predicted directly from the MCMC 
simulation. In ordinary approach to multivariate meta-analysis, predicted effects (on outcomes 
that are not reported) are by-products of the analysis that contribute to the pooled effects4. 
Here we exploit this by using the predicted value directly to inform decision model.  
2.2.3. Indirect meta-analysis and network meta-analysis 
ICMA allows for the comparisons of interventions when there is no head-to-head RCT that 
compared them directly by evaluating the difference between the interventions through at least 
one common comparator16, 17. This method evaluates the relative effectiveness between the 
two interventions using two sets of RCTs that compare each of the interventions with the 
common comparator separately. If, for example, for three interventions A, B, C there is no 
RCT that directly compares A and B but there are RCTs that compared A with C and B with 
C, then the relative effect of A versus B can be estimated indirectly as AB𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡 = AC𝑑𝑖𝑟𝑒𝑐𝑡 
– BC𝑑𝑖𝑟𝑒𝑐𝑡 where AC𝑑𝑖𝑟𝑒𝑐𝑡 and BC𝑑𝑖𝑟𝑒𝑐𝑡 represent the direct evidence from RCTs of the 
treatment effect of A versus C and the treatment effect of B versus C respectively. The method 
extends to NMA combining both direct and indirect evidence from multiple studies of multiple 
interventions1. NMA was used in this paper to obtain HRs for both OS and PFS comparing 
M+P versus P alone, which is an alternative contrast that can be used in health economic 
model as for OS by Collins et al10.  
 
2.3 Methods of cost-effectiveness analysis 
Collins at al. specified a two-state Markov model, including the stable disease (StD) and death 
(D) states, that assessed the cost-effectiveness of (D+P) for the treatment of mHRPC10. Figure 
2 shows the two-state model specified in the HTA report and the three-state model proposed 
in this paper, which includes a progressive disease (PD) state. For the comparison of the 
results of the proposed three-state model with the results of the two-state model reported in 
the HTA, the two-state model was reproduced to ensure that the models (two-state and three-
state) are comparable in terms of input parameters and software used (Excel software was 
used to implement the original HTA model). For clarity, the re-produced two-state model will 
be called the “WinBUGS two-state model” and the original two-state model in the HTA report 
will be called the “HTA two-state model” in this paper. Similarly to the HTA two-state model, 
both the WinBUGS two-state model and WinBUGS three-state model were run for 180 cycles, 
where one cycle represented one month and the time horizon was 15 years. A cohort size of 
10,000 was used in each of the models. 
 
Figure 2: Original HTA model (top) and proposed Bayesian BRMA to predict PFS for the 
specification of a three-state economic Markov model (bottom). 
2.3.1 Transition probabilities 
For the WinBUGS two-state model, the transition probabilities were estimated using the 
Weibull parameters reported in the HTA report, obtained from trial TAX 327. As for the three-
state model, which incorporated a PD state, the transition probabilities for transition from StD 
state to PD state were estimated using parametric Weibull survival modelling on reconstructed 
PFS IPD from SWOG trial, which was one of the RCTs of unlicensed drugs used in the 
sensitivity analysis in the HTA report. It was most comparable trial with TAX 327 (for details 
about the studies see Appendix A and the justification of the choice of the SWOG trial 
Appendix C.2 of the supplement). This transition probability from StD state to PD state was 
obtained for M+P. Transition probability for D+P was in turn calculated by applying the 
predicted PFS HR of D+P versus M+P  to the transition probability of M+P. Transition 
probability for transition from the StD state to death state was obtained from an article on cost-
effectiveness analysis for advance hormone-dependent prostate cancer 18 and was applied to 
the model with no uncertainty as 0.005.  
Survival analysis using the parametric Weibull model was used to implement time-
dependency in the transition probabilities in the economic models (transition probabilities for 
transition from StD state to death state in WinBUGS two-state model; and for transition from 
StD state to PD state in three-state model). Details of this analysis are included in Appendix 
B.1.1 of the supplement. 
Although IPD were reconstructed for (PFS and OS) for the trial selected for estimating the 
transition probability from StD state to PD state, the reconstructed IPD for PFS and OS were 
not paired by patient. Hence, it would not be possible to estimate the transition probabilities 
from PD state to death state using parametric survival analysis performed using reconstructed 
IPD as was the case for transition probability for StD state to PD state.  To overcome this 
issue, transition probabilities were estimated by assuming the mean total survival time was 
equal to the weighted sum of combined survival time from stable disease to progression and 
then to death and the survival time from stable disease directly to death when death occurred 
from other causes. The analysis is described in more detail in Appendix B.1.2 of the 
supplement. 
Once the transition probabilities were obtained for the baseline treatment (here M+P), the HRs 
were applied to them to obtain the transition probabilities for the other two interventions (D+P 
and P alone). For the two-state model, these are the HRs for OS obtained from the HTA 
report. For the three-state model, the predicted HR on PFS from BRMA was used to obtain 
the transition probabilities from StD state to PD state for D+P intervention, whilst the HR 
obtained from the meta-analysis of the three trials evaluating the corticosteroids P(H) 
vs M+P(H) was used to obtain the transition probability from StD to PD state for P.  
2.3.2 Cost 
Cost data comprises drug acquisition and administration cost for each intervention, cost of the 
management of adverse side effects and subsequent follow up cost that included cost of 
further chemotherapy after disease progression, management of side-effects and palliative 
care cost. Cost for each of the interventions used in the WinBUGS 2-state and 3-state models 
were extracted from cost data presented in the HTA report. In the report, costs were 
categorised into three components: namely, (i) the drug acquisition and administration cost, 
(ii) the follow up cost and (iii) the terminal care cost. In the three-state model, the follow up 
costs were divided into portions corresponding to StD state and PD state by taking into 
account that costs of subsequent chemotherapy and hospitalisations accounted for between 
70% and 80% of follow-up costs which most likely occurred post-progression and the 
remaining follow-up cost (20% to 30%) were related to side effects likely to occur prior to 
progression (but may also be associated with the subsequent chemotherapy post-
progression). The annual discount rate of 3.5% was applied from cycle 13 onwards. Details of 
cost analysis are includes in Appendix B.2 of the supplement. 
2.3.3. Quality-adjusted life-years 
Quality-adjusted life-years (QALY) were used as a measure of effect in the cost-effectiveness 
analysis. To estimate the QALY, utility data in the form of HRQoL were required to quantify 
the health status of patients with mHRPC, as well as the impact the interventions had on the 
HRQoL (in terms of disease progression and serious adverse effects).  
Quality of life data used in the HTA two-state model by Collins et al10 were extracted from a 
study conducted by Sandblom and colleagues19. The study was appropriate as it reported 
HRQoL values using a generic HRQoL instrument, the EuroQoL five-dimensional (EQ-5D) 
questionnaire that is required in submissions for technology assessment by NICE, it used the 
population representative of the target population of the HTA; and it provided end-of-life 
HRQoL values of prostate cancer patients in their last year before death. The EQ-5D values 
used in the HTA two-state model were also used in our WinBUGS two-state model as well as 
in the three-state model.  
With the inclusion of a PD state in the three-state model, additional utility data for the PD state 
were required. EQ-5D value used in the two-state models for the StD state were used to 
describe the HRQoL of patients in the PD state (denoted as 𝑈𝑃𝐷) in the three state model. 
This was based on the argument that this utility reflects the patients' HRQoL prior to prostate 
cancer death and the state prior to death would be the PD state. As the EQ-5D value for the 
StD state in the two-state model was used to describe the utility for progressed patients, utility 
for the StD state in the three-state model had to be estimated. This is achieved by splitting the 
patients in the StD state into three groups and using the following EQ-5D values from the 
Sandblom et al. study: (i) EQ-5D values of all patients who died of other causes (denoted as 
𝑈𝑂𝑡ℎ𝑒𝑟 𝑐𝑎𝑢𝑠𝑒𝑠) (ii) EQ-5D values of all patients who were still surviving with prostate cancer 
(denoted as 𝑈𝑆𝑢𝑟𝑣𝑖𝑣𝑖𝑛𝑔) and lastly (iii) 𝑈𝑃𝐷 described earlier. These EQ-5D values, weighted 
by the transition probabilities amount to the utility for the StD state: 
𝑈𝑆𝐷 = 𝑇𝑃𝑆𝑡𝐷𝑈𝑆𝑢𝑟𝑣𝑖𝑣𝑖𝑛𝑔 + 𝑇𝑃𝑆𝑡𝐷𝑡𝑜𝑃𝐷𝑈𝑃𝐷 + 𝑇𝑃𝑆𝑡𝐷𝑡𝑜𝐷𝑒𝑎𝑡ℎ𝑈𝑂𝑡ℎ𝑒𝑟 𝑐𝑎𝑢𝑠𝑒𝑠 
where 𝑇𝑃𝑆𝑡𝐷 is the probability of remaining in StD state, 𝑇𝑃𝑆𝑡𝐷𝑡𝑜𝑃𝐷 the probability of transition 
from StD state to PD state and 𝑇𝑃𝑆𝑡𝐷𝑡𝑜𝐷𝑒𝑎𝑡ℎ the probability of transition from StD state to death 
state without progression. A utility value of zero was assigned to the death state (𝑈𝐷𝑒𝑎𝑡ℎ = 0). 
The utilities for the other states are given in Appendix B.3 of the supplement. Similarly as for 
cost, an annual discount rate of 3.5% was used for discounting the utilities after the first year. 
 
2.3.4. Cost-effectiveness analysis  
For the assessment of the cost-effectiveness of the interventions in each model, the mean 
costs and mean QALYs gained for the interventions and the incremental cost-effectiveness 
ratios (ICERs) for the comparison of the two interventions of interest (M+P and D+P) were 
estimated. Cost effectiveness acceptability curves (CEACs) were generated to compare the 
three interventions. The CEAC and the cost-effectiveness plane were used to compare the 
proposed three-state model with the WinBUGS two-state model (which is expected to be 
comparable to the HTA two-state model) when evaluating the difference between D+P and 
M+P.  
2.4. Software implementation 
IPD were reconstructed from the Kaplan-Meier curves using the DigitizeIt20 and R21. Survival 
analyses were implemented in Stata22. BRMA and the cost-effectiveness models were 
implemented using Markov Chain Monte Carlo (MCMC) simulations  in WinBUGS23, 24, with 
30, 000 MCMC iterations and 15,000 burn-in (iterations that were discarded) for BRMA and 
50,000 iterations and 30,000 burn-in for the cost-effectiveness models. Output data were 
processed using R21.  
 
3. Results 
3.1 Clinical effectiveness 
Kaplan-Meier curves for OS were reported for the four trials in the HTA set. Progression-free 
survival was not reported for TAX 327 and PFS Kaplan-Meier curve was not reported for CCI-
NOV22. Hazard ratios, for individual studies, calculated using the reconstructed IPD were 
comparable with the results reported in the original trials’ publications. HRs on OS and PFS 
reported in the original articles and those obtained from the survival analysis of reconstructed 
IPD are presented in Appendix C of the supplement (Table C1 and C2).  
Table 2 presents all HRs for OS and PFS, obtained from the meta-analyses, including those 
reported in HTA report and obtained by synthesising HRs from reconstructed IPD. Summary 
estimates for the HR of OS comparing M+P with P, obtained by combining estimates from 
survival analysis of reconstructed IPD from the three RCTs that directly compared M+P(H) 
and P(H) (trials in HTA Set excluding TAX 327) were 0.903 (95% CrI 0.751,  1.084) and 
0.901 (95% CrI 0.405, 2.023) using fixed-effect and random-effects meta-analysis 
respectively. The estimates differed slightly from those in the HTA report, which were 0.99 
(95% CI 0.82, 1.20) for both fixed-effect and random-effects. The difference in the HR point 
estimates was largely due to the lower HRs obtained using the reconstructed IPD for trials: 
CCI-NOV22, CALGB 9182 and Berry, compared to the HRs reported in the HTA report. 
However, the 95% credible interval (CrI) estimated using fixed-effect meta-analysis was 
comparable to the 95% CI reported in the HTA report. Hazard ratios comparing the effect of 
D+P versus P(H) on OS were 0.688 (95% CrI 0.523, 0.907) and 0.688 (95% CrI 0.300, 1.604) 
using fixed-effect and random-effects ICMA respectively as compared to the HR of 0.75 (95% 
CI 0.57, 0.99) for random-effects ICMA published in the HTA report. Similarly as for 
comparison of M+P(H) vs. P(H), the estimates of HRs obtained from the reconstructed IPD 
were lower than those reported in the HTA report.  
 
Table 2: OS and PFS HRs estimated from traditional and indirect comparison meta-analysis 
using reconstructed IPD 
  Hazard Ratio (95% Confidence/CrI) 
 
Overall Survival 
 
Progression-free 
Survival 
Evidence Synthesis 
Reported in  
HTA report 
Estimated using  
reconstructed IPD   
Estimated using 
reconstructed IPD 
     
Meta-analysis (M+P/P) 
    
Fixed Effect Analysis 0.99 (0.82, 1.20) 0.903 (0.751, 1.084) 
 
0.641 (0.532, 0.772) 
Random Effects Analysis 0.99 (0.82, 1.20) 0.901 (0.405, 2.023) 
 
0.619 (0.170, 2.048) 
     
Relative estimate (D+P/M+P) 0.76 (0.62, 0.94)^ 0.76 (0.620, 0.936)^ 
 
0.618 (0.383, 0.941)* 
     
Indirect comparison 
(D+P(H)/P(H)) 
    
Fixed Effect Analysis Not performed 0.688 (0.523, 0.907) 
 
0.396 (0.307, 0.512) 
Random Effects Analysis 0.75 (0.57, 0.99) 0.688 (0.300, 1.604) 
 
0.381 (0.107, 1.280) 
          
^HRs estimated using TAX 327 trial IPD / re-constructed IPD 
*HR predicted using BRMA model 
 
HR for PFS comparing M+P(H) versus P(H), obtained from fixed-effect and random-effects 
meta-analyses of estimates from reconstructed IPD, were 0.641 (95% CrI 0.532, 0.772) and 
0.619 (95% CrI 0.170, 2.048) respectively. No summary estimate for this comparison was 
reported in the HTA report. Bayesian BRMA model was used to jointly model the correlated 
treatment effects on OS and PFS to enable the prediction of treatment effect of D+P versus 
M+P on PFS for trial TAX 327. The predicted PFS HR for the comparison of D+P versus M+P 
(for TAX 327) was 0.618 (95% CrI 0.383, 0.941). HRs comparing the effect of D+P versus 
P(H) on PFS were 0.396 (95% CrI 0.307, 0.512) and 0.381 (95% CrI 0.107, 1.280) from fixed-
effect and random-effects ICMA respectively.  
 3.2 Cost effectiveness 
Table 3 presents the differences in cost and QALY and ICERs for D+P compared to M+P, for 
all three models. The details of the costs of interventions and the mean QALY per patient for 
each of the interventions in the economic models are presented in Appendix C.3.  Results 
showed that  the ICER obtained from the proposed three-state model, using a predicted PFS 
HR of 0.618 (95% CrI: 0.383 to 0.941) for D+P versus M+P was £21966 compared to £30026 
obtained from the WinBUGS two-state model (£32706 in the HTA report). Hence, by 
implementing the three-state model and taking into account the cost and QALY in the PD 
state, the ICER estimated was lower than that of the HTA (or WinBUGS) two-state model. 
 
Table 3: Clinical and cost effectiveness of the HTA two-state model and proposed three-
state model 
  
HTA two-state 
model 
WinBUGS 
two-state model 
WinBUGS 
three-state model 
    
Clinical Effectiveness     
Predicted PFS HR (D+P/M+P) 
Not applicable in 
HTA report 
Not required 0.618 (0.383, 0.941) 
    
Cost-Effectiveness    
Difference in Cost, Mean (SE) 5049 4624 (4407.83) 5350 (4243.95) 
    
Difference in QALY, Mean (SE) 0.15437 0.154 (0.0676) 0.244 (0.0638) 
    
ICER 32706 30026 21966 
    
Differences were calculated as estimate for (D+P) minus estimate for (M+P) 
 
The net benefit for each intervention and the probability that each intervention was cost-
effective at £20000 and £30000 are presented in Table 4. At £20000, for the two-state models, 
M+P had the highest probability of being cost-effective amongst all three interventions (but the 
same as for P intervention in the HTA model) while D+P had the highest probability of being 
cost-effective in the three-state model.  However, at £30000, D+P had the highest probability 
of being cost-effective amongst all three interventions for all the models, with the probability 
being as high as 0.52 in the three-state model compared to 0.44 in the two-state model. Figure 
3 shows cost-effectiveness acceptability curves, over a range of willingness to pay thresholds, 
comparing all the interventions using the WinBUGS two-state model and WinBUGS three-
state model. At £20000, M+P had the highest probability cost-effective in the two-state model 
while D+P had the highest probability cost-effective in the three-state model. However, at 
£30000,  D+P had the highest probability of being cost-effective amongst all three 
interventions in both models. 
 
Table 4: Net benefit and probability cost-effectiveness table 
  
Probability cost-
effectiveness Net Benefit (95% Credible Interval) 
Intervention £20,000 £30,000 £20,000 £30,000 
     
HTA two-state model     
P 0.39 0.33 Not Reported Not Reported 
M+P 0.39 0.29 Not Reported Not Reported 
D+P (3 weekly) 0.22 0.38 Not Reported Not Reported 
     
WinBUGS two-state 
model     
P 0.32 0.28 4417 (-5119, 12360) 12512 (1648, 22500) 
M+P 0.36 0.28 5023 (-2327, 11680) 13153 (4116, 21800) 
D+P (3 weekly) 0.32 0.44 3479 (-5749, 12560) 13149 (1859, 24430) 
     
WinBUGS three-
state model     
P 0.31 0.27 6829 (-4364, 19720) 15320 (830, 33820) 
M+P 0.34 0.21 7810 (1724, 13090) 16704 (9635, 23240) 
D+P (3 weekly) 0.36 0.52 7331 (-790, 15240) 18660 (9394, 27860) 
          
 
 
 
 
 
 
 
 Figure 3: Cost-effectiveness acceptability curves for all three interventions – two-state (left) and 
three-state (right) model using direct HR of P versus M+P  
 
Figure 4 shows cost-effectiveness acceptability curves and cost-effectiveness plane for 
comparison of the WinBUGS two-state model with the three-state model (using comparison 
of D+P with M+P). The cost-effectiveness acceptability curves showed that after 
approximately £10000 willingness-to-pay threshold, the probability that D+P was more cost-
effective than M+P was higher in the three-state model than the two-state model. For example, 
at £30000, the probability was around 0.7 for the three-state model compared to 0.5 for the 
two-state model.  
 
Figure 4: Cost-effectiveness acceptability curves (left) and cost-effectiveness plane (right) for 
WinBUGS two-state and three-state economic models 
 
The cost-effectiveness plane showed that D+P was more effective (in terms of utility) than 
M+P for both the two-state and three-state models, although the certainty of its effectiveness 
was greater in the three-state model than the two-state model as all the 50000 Monte Carlo 
simulations points of the three-state model (green circles) were in the positive utility difference 
area. Besides being more effective, D+P was also more costly than M+P. However, the degree 
of uncertainty for the difference in cost of the two interventions were comparable for both 
models. 
4. Discussion 
We have investigated the use of multi-parameter evidence synthesis, and in particular 
bivariate meta-analysis, for purpose of allowing all available evidence to inform health 
economic decision model. The methodology was applied to motivating example of cost-
effectiveness of docetaxel (D+P) in mHRPC. We reviewed the original HTA conducted by 
Collins et al, who implemented two-state Markov model for purpose of cost-effectiveness 
analysis. The model consisted of stable disease and death states, where the stable disease 
included both the patients who were stable and those who progressed. The clinical 
effectiveness estimates used in the model were based on data from the systematic review of 
RCTs which did not contain any estimate of the effect of docetaxel (in any combination) on 
PFS, only an estimate of the treatment effect on OS. The aim of our research was to 
investigate how inclusion of a predicted estimate of the effect of docetaxel on PFS would 
impact on the cost-effectiveness estimates.  We showed how such predicted estimate can be 
obtained and how it can enable implementation of three-state Markov model comprising of 
stable disease state, separate progressive disease state and death state    
Conducting bivariate meta-analysis by modelling jointly correlated treatment effects on OS 
and PFS enabled us to predict the effect of docetaxel (with prednisolone) on PFS in TAX 327 
study which was the only RCT, at the time of technology assessment, evaluating docetaxel 
and which reported the treatment effect on OS only. To use the predicted effect to inform the 
three-state model, further analysis was conducted to estimate other parameters, such as 
transition probabilities between the states and utilities for the stable disease and the 
progressive disease  states, now being the separate states. 
The cost effectiveness analysis resulted in much lower ICER obtained from the three-state 
model compared to the two-state model. This was due to combining stable and progressed 
patients in the single state in the two state model, which likely underestimated the average 
utility. The two-state model used utility reported by Sandblom et al19 who measured EQ-5D 
twelve months prior to death. Taking into account that the median overall survival is 
approximately 18 months, 12 months prior to death would be at median six months’ time from 
start of treatment which is equal to the median time to progression. Therefore this 
measurement of HRQoL corresponds only to patients who progressed. Hence the utility of the 
StD state in the two state model seems underestimated as some of the patients in the StD 
state, for a considerable amount of time, are progression free and therefore should have 
higher utility. In the three-state model we use the same utility in the PD state as in the original 
two-state model, but allow for the utility in the StD state to vary over time allowing a proportion 
of patients remaining in the StD state in each cycle to have a higher utility, leading to higher 
average utility. In addition, most patients leaving the StD state transition to progression and 
the difference in transition probabilities (for transition out of StD state) between treatments is 
higher in the three-state model than in the two state model. This is because the HR on PFS is 
higher than HR on OS. Therefore the difference between treatments in rates of patients 
leaving the StD state is also higher in the three-state model. This leads to a larger average 
difference in utility which is relatively larger than the difference in average incremental cost, 
as substantial care costs are still required post-progression relative to the cost of treatment 
before progression. This substantial increase in the QALY gained led to the much smaller 
ICER obtained from the three-state model compared to the two-state model. 
There were some limitations of our research. One was the variability in the definitions of the 
progression endpoints (for details see Appendix A.1 of the supplement). Standardising the 
definition of the progression endpoint for all the RCTs, however, would require IPD from each 
of the trials, which is not achievable within the resources of this project. Another limitation was 
a small number of studies in the bivariate meta-analysis. However, careful analysis of the 
results indicated that the predicted effect on PFS in Tax 327 had converged in the MCMC 
simulation. Moreover, the obtained estimate was comparable with the estimate of the effect of 
docetaxel combination therapy reported in SWOG trial (not included in the meta-analysis due 
to unlicensed comparator, see Table C2 in the supplement) obtained from the digitised data, 
but with appropriately larger uncertainty.   
In conclusion, we have illustrated that a careful synthesis of all available evidence can help 
valuable data, otherwise discarded, being used to better inform the decision making process. 
Multivariate evidence synthesis is, therefore, a valuable tool in synthesis of evidence for 
medical decision making. 
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Appendix A: Summary of synthesis of evidence conducted by Collins et al 
As part of the Health Technology Assessment (HTA) (Collins et al., 2007) evaluating the 
clinical- and cost-effectiveness of docetaxel in combination with either prednisone or 
prednisolone (D+P) for the treatment of mHRPC, a scoping search for studies evaluating the 
clinical- and cost-effectiveness of D+P was conducted. As only one RCT was identified to have 
compared D+P with mitoxantrone plus prednisone (M+P) and no other RCT compared D+P 
with any other possible interventions, RCTs that assessed mitoxantrone in combination with 
a corticosteroid compared with any chemotherapy regimen or best supportive care or placebo 
were also included in the scoping search. Extension of the studies selection to include studies 
that evaluated mitoxantrone in combination with a corticosteroid was to allow for the 
comparison between D+P and other relevant interventions using mitoxantrone in combination 
with a corticosteroid as a common comparator in indirect comparison analysis. In total, seven 
RCTs were identified based on the inclusion criteria, of which three RCTs used docetaxel 
compared with M+P, three RCTs used mitoxantrone plus a corticosteroid (M+P/H) compared 
with a corticosteroid (P/H) and one RCT used M+P compared with mitoxantrone plus 
prednisone plus clodronate (M+P+Clo). The three RCTs that included docetaxel had 
docetaxel in the following combination: D+P, docetaxel with estramustine (D+E) and docetaxel 
with estramustine and prednisone (D+E+P).  All studies with details of interventions and 
reported outcomes are presented in Table A1. 
Table A.1  
HTA 
Set 
Trial 
No. 
of arms 
Reference 
Treatment 
Comparative 
Treatment(s) 
Total no. 
of patients 
OS 
data 
PFS 
data 
        
Set 
1* 
CCI-NOV22 
(Tannock et al., 1996) 
2 M+P P 161 Yes Yes 
       
CALGB 9182 
(Kantoff et al., 1999) 
2 M+H H 242 Yes Yes 
       
Berry et al. 
(Berry et al., 2002) 
2 M+P P 120 Yes Yes 
       
TAX 327 
(Tannock et al., 2004) 
3 M+P 
D+P  
1006 Yes No 
D1+P 
                
        
Set 2 
Ernst 
(Ernst et al., 2003) 
2 M+P M+P+Cl 209 Yes Yes 
       
SWOG 
(Petrylak et al., 2004) 
2 M+P D+E 674 Yes Yes 
       
Oudard 
(Oudard et al., 2005) 
3 M+P 
D70+E+P 
127 Yes Yes 
D35+E+P 
                
*HTA set in the main manuscript (licensed interventions) 
†unlicensed interventions used by Collins et al. in sensitivity analysis (we use SWOG data to obtain some of 
the transition probabilities) . 
 A.1 Definitions of outcome measures 
Definitions of OS were consistent for the four RCTs in HTA Set except for trial Berry, where 
OS was not explicitly defined9. Overall survival was defined as the time from the date of 
randomisation to the date of death or censored at the date when the patient was last known 
to be alive. There were inconsistencies in the definition of progression across the three RCTs 
in HTA Set (excluding trial TAX327 which did not report PFS). Specifically, PFS reported for 
CALGB 918210 was defined as the time from the date of randomisation to the date of 
progression or death, whichever occurred first. Neither PFS nor time to progression (TTP) was 
reported for trial CCI-NOV2212; however, the HTA report presented TTP estimates for this trial. 
TTP was reported by Berry and colleagues 9 but no explicit definition for TTP was provided.   
 
Appendix B: Cost-effectiveness analysis methods 
 
For the cost-effectiveness assessment of D+P in the HTA report, two separate analyses were 
performed. This is due to the unlicensed status of some of the treatment regimens. The first 
analysis looked at three interventions (that are licensed at the time of the HTA report 
submission), namely D+P, M+P(H) and P(H). The second analysis looked at eight 
interventions, including the three in the first analysis and the following five: D1+P, D+E, 
D70+E+P, D35+E+P, M+P+Clo. Due to the unlicensed status of the interventions in the 
second analysis, the economic decision making in this HTA report was based on the results 
of the first analysis. In the research that follows in this paper, the focus is on the cost-
effectiveness assessment of the interventions compared in the first analysis. Data from SWOG 
trial were used to inform the utility in the cost-effectiveness analysis.  
To develop the economic models, data for the construction of transition probabilities, definition 
of costs and utilities for each of the interventions need to be extracted. These data can be 
extracted from reviews, single RCT or evidence synthesis from a number of trials/studies. 
Specifications of the transition probabilities, cost and utilities are described in sections 2.3.1, 
2.3.2 and 2.3.3 respectively. 
 
B.1 Transition probabilities 
For the WinBUGS two-state model, the transition probabilities were estimated using the 
Weibull parameters reported in the HTA report, which used IPD from trial TAX 327. This was 
for consistency with the parameters used in the HTA model. As for the three-state model, 
which incorporated a PD state, the transition probabilities for transition from StD state to PD 
state were estimated using parametric Weibull survival modelling on reconstructed PFS IPD 
from one of the six RCTs (excluding trial TAX 327) in the HTA report.  
The selection criteria for the RCT to be used for estimating the transition probabilities for 
treatment arm M+P are: (i) comparable OS profile of the selected trial and trial TAX 327; (ii) 
selected trial having a mean time of progression closest to the reported mean cycle of M+P 
administrated in trial TAX 327 (that is: 5.9 cycles as reported in the HTA report). As PFS was 
not recorded for TAX 327, selection criteria (ii) is based on the assumption that the patients in 
trial TAX 327 M+P arm were administrated M+P till progression. The mean number of cycles 
of M+P administrated was then used as a crude approximation of the ‘potential’ mean time to 
progression for patients administrated M+P in trial TAX 327. Transition probability for transition 
from the StD state to death state was obtained from an article on cost-effectiveness analysis 
for advance hormone-dependent prostate cancer (Lu et al., 2012). In the absence of patient-
level data on both OS and PFS for any of the interventions, the transition probability for 
transition from PD state to death state could not be estimated. Methods for the estimation of 
(i) transition probabilities using parametric Weibull survival model and (ii) transition 
probabilities for transition from PD state to death state in the three-state model are described 
in the next two subsections. 
 
B.1.1 Transition probabilities estimated using parametric Weibull survival model 
Survival analysis using the parametric Weibull model was used to implement time-
dependency in the transition probabilities in the economic models (transition probabilities for 
transition from StD state to death state in WinBUGS two-state model; and transition 
probabilities for transition from StD state to PD state in three-state model). The Weibull 
distribution takes the following probability density function: 
𝑓(𝑡) =  𝜆𝛾𝑡𝛾−1𝑒𝑥𝑝(−𝜆𝑡𝛾) 
where 𝜆 gives the scale of the distribution and 𝛾 defines the shape. The hazard function for 
this distribution is therefore:  
ℎ(𝑡) =  𝜆𝛾𝑡𝛾−1 
with a cumulative hazard function of: 
𝐻(𝑡) =  𝜆𝑡𝛾 
where the survival function is related to the cumulative hazard function in the following form: 
𝑆(𝑡) = 𝑒𝑥𝑝[−𝐻(𝑡)] 
Since hazards are instantaneous, these need to be converted to a transition probability for a 
given period, such as a Markov cycle. Using the survival function, transition probability 
between time-points (𝑡 − 𝑢) and 𝑡, denoted as 𝑇𝑃(𝑡𝑢) where 𝑢 is the cycle length, was defined 
as one minus the ratio of the survival function at the end of the interval to the survival function 
at the beginning of the interval. This function defined as:  
𝑇𝑃(𝑡𝑢) = 1 − 𝑆(𝑡)/𝑆(𝑡 − 𝑢) 
 
was re-written using the cumulative hazed function as: 
𝑇𝑃(𝑡𝑢) = 1 − 𝑒𝑥𝑝[−𝐻(𝑡)]/𝑒𝑥𝑝[−𝐻(𝑡 − 𝑢)] 
= 1 − 𝑒𝑥𝑝[𝐻(𝑡 − 𝑢) − 𝐻(𝑡)] 
Therefore, transition probability was defined using the Weibull parameters as follows:  
𝑇𝑃(𝑡𝑢) = 1 − 𝑒𝑥𝑝[𝜆(𝑡 − 𝑢)
𝛾 − 𝜆𝑡𝛾] 
In the HTA report, results of the Weibull survival analysis model were presented in the form of 
the regression coefficients of the intercept and scale parameters. These two parameters are 
expressed in terms of the Weibull parameters,  and , as follows: 
𝜆 = 𝑒𝑥𝑝(−𝛽/𝛼) 
𝛾 =  
1
𝛼
 
where 𝛽 is the intercept and 𝛼 is the scale regression coefficient parameters from the Weibull 
survival analysis. 
When performing the probabilistic analysis, the covariance between the intercept and scale 
regression parameter from the Weibull survival analysis were also incorporated in the 
WinBUGS two-state model. This was achieved by using the Cholesky decomposition matrix 
derived from the covariance matrix obtained from the Weibull survival regression model. Given 
a covariance matrix of the form:  
𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒, 𝐶 =  (
𝑎 𝑏
𝑏 𝑐
) 
the Cholesky decomposition matrix takes the form: 
𝐷 =  (
√𝑎 0
𝑏
√𝑎
√𝑐 −
𝑏2
𝑎
) 
such that 𝐶 = 𝐷 𝐷∗ where 𝐷∗ denotes the conjugate transpose of 𝐷. Cholesky decomposition 
matrices of the covariance matrices for the interventions, D+P and M+P, were calculated 
independently and applied to the transition probabilities of D+P and M+P respectively in the 
WinBUGS two-state model to allow for the correlation between the intercept and scale 
parameters when sampling the random normal draws for the two parameters. Assuming that 
the Cholesky decomposition matrix of the covariance matrix for M+P is: 
𝐷𝑀+𝑃 =  (
𝑢𝐷,𝑀+𝑃 0
𝑣𝐷,𝑀+𝑃 𝑤𝐷,𝑀+𝑃
) 
the transition probability incorporating parameter uncertainties for transition from StD state to 
death state for M+P is defined as: 
𝑇𝑃𝐷,𝑀+𝑃(𝑡𝑢) = 1 − 𝑒𝑥𝑝[𝐻𝐷(𝑡 − 𝑢) − 𝐻𝐷(𝑡)] 
𝑇𝑃𝐷,𝑀+𝑃(𝑡𝑢) = 1 − 𝑒𝑥𝑝[𝜆𝐷,𝑀+𝑃(𝑡 − 𝑢)
𝛾𝐷,𝑀+𝑃 − 𝜆𝐷,𝑀+𝑃𝑡
𝛾𝐷,𝑀+𝑃] 
where: 
𝜆𝐷,𝑀+𝑃 = exp (
−𝛽𝐷,𝑀+𝑃
𝛼𝐷,𝑀+𝑃
) 
𝛾𝐷,𝑀+𝑃 =  
1
𝛼𝐷,𝑀+𝑃
 
and 
𝛽𝐷,𝑀+𝑃 = 𝛽𝑀+𝑃 + 𝑢𝐷,𝑀+𝑃𝑍𝛽,𝐷,𝑀+𝑃 
𝛼𝐷,𝑀+𝑃 = 𝛼𝑀+𝑃 + 𝑣𝐷,𝑀+𝑃𝑍𝛽,𝐷,𝑀+𝑃 + 𝑤𝐷,𝑀+𝑃𝑍𝛼,𝐷,𝑀+𝑃 
where 𝛽𝑀+𝑃 and 𝛼𝑀+𝑃 are the intercept and scale regression coefficients for M+P presented 
in the HTA report; and 𝑍𝛽,D,𝑀+𝑃 ~ 𝑁𝑜𝑟𝑚𝑎𝑙(0, 1) and 𝑍𝛼,D,𝑀+𝑃 ~ 𝑁𝑜𝑟𝑚𝑎𝑙(0, 1). 
Transition probabilities of interventions D+P and M+P for the WinBUGS two-state model were 
calculated using the regression coefficients from the HTA report (Table 28 (Collins et al., 
2007)). Transition probabilities for P were calculated by applying the HR of P versus M+P or 
HR of P versus D+P to the hazard rates of M+P and D+P in the transition probabilities 
respectively. Therefore, assuming that the transition probability for M+P is given by:  
𝑇𝑃𝑀+𝑃(𝑡𝑢) = 1 − 𝑒𝑥𝑝[𝐻(𝑡 − 𝑢) − 𝐻(𝑡)] 
and with a HR for P versus M+P, denoted as 𝐻𝑅𝑃 𝑀+𝑃⁄ , the transition probability for P is given 
by: 
𝑇𝑃𝑃(𝑡𝑢) = 1 − 𝑒𝑥𝑝{𝐻𝑅𝑃 𝑀+𝑃⁄ [𝐻(𝑡 − 𝑢) − 𝐻(𝑡)]} 
= 1 − 𝑒𝑥𝑝[𝐻(𝑡 − 𝑢) − 𝐻(𝑡)]𝐻𝑅𝑃 𝑀+𝑃⁄  
Uncertainty associated with the HR was incorporated in the model by assigning a normal 
distribution to the logarithm of the HR as follows: 
𝐿𝐻𝑅 ~ 𝑁𝑜𝑟𝑚𝑎𝑙(?̅?, 𝜎2) 
where ?̅? and 𝜎2 are the mean and variance estimate of the LHR from random-effects meta-
analysis. 
For the three-state model, the set of transition probabilities for intervention M+P was 
calculated using regression coefficients of the parameters of a Weibull survival model for PFS 
using re-constructed IPD from one of the RCTs in HTA Full Set selected based on the criteria 
outlined above. As no PFS patient-level data was available for the interventions D+P and P, 
transition probabilities for each of the interventions were calculated by applying their HR with 
respect to M+P to the transition probabilities of M+P. Similarly, uncertainty associated with 
each of the HRs was included in the respective models by assigning normal distribution to the 
LHRs. 
 
B.1.2. Transition probabilities from PD state to death state (three-state model) 
Although IPD were reconstructed for PFS (together with OS) for the trial selected for 
estimating the transition probability from StD state to PD state, the reconstructed IPD for PFS 
and OS were not paired by patient. Hence, it would not be possible to estimate the transition 
probabilities from PD state to death state using parametric survival analysis performed using 
reconstructed IPD as described in the previous section. To overcome this issue, transition 
probabilities were estimated by assuming the mean total survival time was equal to the 
weighted sum of combined survival time from stable disease to progression and then to death 
and the survival time when death occurred from other causes: 
𝑚𝑒𝑎𝑛(𝑇𝑜𝑡𝑎𝑙 𝑇𝑖𝑚𝑒)
= 𝑊𝑆𝑡𝐷𝑡𝑜𝑃𝐷𝑡𝑜𝐷𝑒𝑎𝑡ℎ[𝑚𝑒𝑎𝑛(𝑇𝑖𝑚𝑒𝑆𝑡𝐷𝑡𝑜𝑃𝐷) + 𝑚𝑒𝑎𝑛(𝑇𝑖𝑚𝑒𝑃𝐷𝑡𝑜𝐷𝑒𝑎𝑡ℎ)]
+  𝑊𝑆𝑡𝐷𝑡𝑜𝐷𝑒𝑎𝑡ℎ𝑚𝑒𝑎𝑛(𝑇𝑖𝑚𝑒𝑆𝑡𝐷𝑡𝑜𝐷𝑒𝑎𝑡ℎ) 
where 𝑚𝑒𝑎𝑛(𝑇𝑖𝑚𝑒𝑆𝑡𝐷𝑡𝑜𝑃𝐷) defines the mean time that patients stayed in the StD state before 
transition to the PD state; 𝑚𝑒𝑎𝑛(𝑇𝑖𝑚𝑒𝑃𝐷𝑡𝑜𝐷𝑒𝑎𝑡ℎ) and 𝑚𝑒𝑎𝑛(𝑇𝑖𝑚𝑒𝑆𝑡𝐷𝑡𝑜𝐷𝑒𝑎𝑡ℎ) define the mean 
time for PD state to death state and StD state to death state respectively; W defines the weight 
assigned to the mean time and is related to the number of patients who transition through the 
two potential pathways in the economic model as shown in Error! Reference source not 
found. (bottom), from stable disease to death either with or without disease progression. 
As the proportion of patients who died of causes unrelated to prostate cancer was expected 
to be small (<1%), we assumed that 𝑊𝑆𝑡𝐷𝑡𝑜𝐷𝑒𝑎𝑡ℎ → 0, therefore 𝑊𝑆𝑡𝐷𝑡𝑜𝑃𝐷𝑡𝑜𝐷𝑒𝑎𝑡ℎ → 1. Hence,  
𝑚𝑒𝑎𝑛(𝑇𝑜𝑡𝑎𝑙 𝑇𝑖𝑚𝑒) = 𝑊𝑆𝑡𝐷𝑡𝑜𝑃𝐷𝑡𝑜𝐷𝑒𝑎𝑡ℎ[𝑚𝑒𝑎𝑛(𝑇𝑖𝑚𝑒𝑆𝑡𝐷𝑡𝑜𝑃𝐷) + 𝑚𝑒𝑎𝑛(𝑇𝑖𝑚𝑒𝑃𝐷𝑡𝑜𝐷𝑒𝑎𝑡ℎ)] 
= 𝑚𝑒𝑎𝑛(𝑇𝑖𝑚𝑒𝑆𝑡𝐷𝑡𝑜𝑃𝐷) + 𝑚𝑒𝑎𝑛(𝑇𝑖𝑚𝑒𝑃𝐷𝑡𝑜𝐷𝑒𝑎𝑡ℎ) 
and therefore, 
𝑚𝑒𝑎𝑛(𝑇𝑖𝑚𝑒𝑃𝐷𝑡𝑜𝐷𝑒𝑎𝑡ℎ) = 𝑚𝑒𝑎𝑛(𝑇𝑜𝑡𝑎𝑙 𝑇𝑖𝑚𝑒) − 𝑚𝑒𝑎𝑛(𝑇𝑖𝑚𝑒𝑆𝑡𝐷𝑡𝑜𝑃𝐷) 
Assuming that the survival data for patients from PD to death follows an exponential survival 
distribution, the transition probability between time-points (𝑡 − 𝑢) and 𝑡, denoted as 𝑇𝑃(𝑡𝑢) 
where 𝑢 is the cycle length, is defined as follows: 
𝑇𝑃(𝑡𝑢) = 1 − 𝑒𝑥𝑝{𝜆(𝑡 − 𝑢)
𝛾 − 𝜆𝑡𝛾} 
= 1 − 𝑒𝑥𝑝(−𝜆𝑢) 
where 𝛾 = 1 for the exponential survival model.  
As the hazard rate, 𝜆 =
1
𝑚𝑒𝑎𝑛(𝑇𝑖𝑚𝑒)
,  
𝑇𝑃(𝑡𝑢) = 1 − 𝑒𝑥𝑝 (
−𝑢
𝑚𝑒𝑎𝑛(𝑇𝑖𝑚𝑒)
) 
For M+P and D+P, the 𝑚𝑒𝑎𝑛(𝑇𝑜𝑡𝑎𝑙 𝑇𝑖𝑚𝑒) for each of the interventions were estimated using 
the mean survival time calculated from the reconstructed OS IPD of trial TAX 327. For P, the 
mean survival time was estimated by a random-effect meta-analysis of the log hazard rate of 
the three RCTs that had a P treatment regimen arm. 
As PFS endpoint were not recorded for trial TAX 327, the mean number of cycles of drug 
reported in the HTA report were used to represent the mean time from stable disease to 
progression, 𝑚𝑒𝑎𝑛(𝑇𝑖𝑚𝑒𝑆𝑡𝐷𝑡𝑜𝑃𝐷), based on the assumption that patients stopped drug 
treatment on the onset of disease progression. Mean number of cycles of drug P was not 
reported in the HTA report. Therefore, the mean time to progression was also estimated using 
meta-analysis of the log hazard rate of the two RCTs that reported PFS data for P. 
Transition probabilities for transition from PD state to death state for each intervention were 
therefore calculated using the equation: 
𝑇𝑃(𝑡𝑢) = 1 − 𝑒𝑥𝑝 (
−𝑢
[𝑚𝑒𝑎𝑛(𝑇𝑜𝑡𝑎𝑙 𝑇𝑖𝑚𝑒) − 𝑚𝑒𝑎𝑛(𝑇𝑖𝑚𝑒𝑆𝑡𝐷𝑡𝑜𝑃𝐷)]
) 
Uncertainty associated with the mean survival time or log hazard rate were also incorporated 
using normal distributions and propagated in the economic model. As the exponential survival 
model is a single parameter model, Cholesky decomposition was not required for defining the 
uncertainty. 
 
B.2. Cost 
Cost data comprises drug acquisition and administration cost for each interventions, cost of 
the management of adverse side effects and subsequent follow up cost that included cost of 
further chemotherapy after disease progression, management of side-effects and palliative 
cost. Cost for each of the interventions to be used in the WinBUGS 2-state and 3-state model 
were extracted from cost data presented in the HTA report. In the report, costs were 
categorised into three components: namely, (i) the drug cost, (ii) the follow up cost and (iii) the 
terminal care cost. Drug cost included cost of acquisition and administration of each 
intervention.  
Follow up cost included the cost of managing side-effects, subsequent chemotherapies and 
hospitalisation for palliative care. Terminal care costs were one-off costs used to incorporate 
the cost of caring for patients in the last month of life. As stated in the HTA report, terminal 
care cost data were not recorded in the trial (TAX 327), hence these costs were estimated 
from patients who died in the first six months after entering the trial. In the absence of costs 
per cycle for follow up cost, these costs were assigned and calculated as one-off cost, in a 
similar fashion as terminal care cost, as patient died. Cost data for interventions D+P and M+P 
were estimated using patient level data from trial TAX 327 while cost data for P were estimated 
using published cost-effectiveness analyses by Bloomfield and colleagues (Bloomfield et al., 
1998). 
Gamma distribution was used to represent uncertainty in the follow up costs and terminal care 
costs. Drug costs for each of the interventions were calculated based on the mean number of 
cycles of drugs administrated. Normal distribution was used to describe the number of cycles 
of drugs administrated to reflect uncertainty in the drug costs. 
For the WinBUGS two-state model, the total costs were calculated as the summation of all 
three categories of costs. For the three-state model, drug costs and terminal care costs were 
calculated in a similar way to that calculated in the WinBUGS two-state model while follow-up 
costs were calculated by dividing the follow-up costs into two unequal parts (using a parameter 
defined as 𝜓 in the equations that follow).  
Costs of subsequent chemotherapy and hospitalisations accounted for between 70% and 80% 
of follow-up costs which most likely occurred post-progression and the remaining follow-up 
cost (20% to 30%) were related to side effects likely to occur prior to progression (but may 
also be associated with the subsequent chemotherapy post-progression). Therefore the follow 
up costs were divided into portions corresponding to StD state and PD state. 
As the base case analysis for the three-state model, 75% (𝜓 = 0.75)  of the follow-up costs 
were assigned to the PD state to account for the cost of subsequent chemotherapy, managing 
side-effects and hospitalisations post-progression. Computation of these costs were based on 
the number of patients who died per cycle while the remaining 25% of the costs that were 
assigned to the StD state were computed based on the number of patients who progressed 
per cycle. Follow-up costs were assigned as one-off cost in a similar way as the WinBUGS 
two-state model.  
In the WinBUGS two-state model, follow-up costs were calculated based on patients died per 
cycle as: 
𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑠𝑡𝐹𝑈 = ∑(𝐶𝑜𝑠𝑡𝐹𝑈,𝑖 × 𝑁𝐷𝑖𝑒𝑑,𝑖)
180
𝑖=1
 
where 𝐶𝑜𝑠𝑡𝐹𝑈,𝑖 represents follow-up cost data for cycle i, and 𝑁𝐷𝑖𝑒𝑑,𝑖 represents the number of 
patients who died in cycle i. 
For the three-state model, the follow-up costs were calculated as:  
𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑠𝑡𝐹𝑈 = 𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑠𝑡𝑆𝑡𝐷𝐹𝑈 + 𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑠𝑡𝑃𝐷𝐹𝑈 
where: 
𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑠𝑡𝑆𝑡𝐷𝐹𝑈 = ∑[(1 − 𝜓) × 𝐶𝑜𝑠𝑡𝐹𝑈,𝑖 × 𝑁𝑃𝑟𝑜𝑔𝑟𝑒𝑠𝑠𝑒𝑑,𝑖]
180
𝑖=1
 
𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑠𝑡𝑃𝐷𝐹𝑈 = ∑(𝜓 × 𝐶𝑜𝑠𝑡𝐹𝑈,𝑖 × 𝑁𝐷𝑖𝑒𝑑,𝑖)
180
𝑖=1
 
𝜓 represents the proportion of follow-up costs associated with the PD state (termed “division 
factor”) and 𝑁𝑃𝑟𝑜𝑔𝑟𝑒𝑠𝑠𝑒𝑑,𝑖 represents the number of patients who progressed in cycle i. 
Sensitivity analyses for assessing different proportions of follow-up costs associated with the 
PD state are described in Section Error! Reference source not found.. An annual discount 
rate of 3.5% was used for discounting the cost after the first year.  
 
B.3 Utility 
Utility for StD state in the WinBUGS two-state model was defined using a beta distribution with 
parameter values Beta(21.1, 18.1), derived from a mean EQ-5D HRQoL of 0.538 (95% CI: 
0.461 to 0.615) as reported in the study by Sandblom and colleagues (Sandblom et al., 2004). 
For the three-state model, the utility distribution, Beta(21.1, 18.1), for the StD in the two-state 
model was assigned as the utility distribution for the PD state as the corresponding mean EQ-
5D of 0.538 represents the HRQoL of all patients 12 months prior to death. Two additional 
EQ-5D values as discussed in Section 2.3.3 were extracted from the Sandblom study 
(Sandblom et al., 2004), they were the EQ-5D for patients who were still surviving at the time 
of analysis of the study, EQ-5D = 0.770 (95% CI: 0.755 to 0.785), and EQ-5D of patients who 
died of other non-prostate cancer related death, EQ-5D = 0.564 (95% CI: 0.497 to 0.631). 
These two utility data were defined in the economic model using the following beta 
distributions, Beta(581.3, 173.6) and Beta(29.1, 22.5) respectively. Utility for the StD state was 
calculated based on the method described in Section 2.3.3 using two additional EQ-5D values 
extracted from the Sandblom study (Sandblom et al., 2004), they were the EQ-5D for patients 
who were still surviving at the time of analysis of the study, EQ-5D = 0.770 (95% CI: 0.755 to 
0.785), and EQ-5D of patients who died of other non-prostate cancer related death, EQ-5D = 
0.564 (95% CI: 0.497 to 0.631). These two utility data were defined in the economic model 
using the following beta distributions, Beta(581.3, 173.6) and Beta(29.1, 22.5) respectively to 
derive the utility for the StD state. 
As the utilities defined were selected to reflect the general HRQoL of patients with advanced 
prostate cancer and were independent of the interventions administrated by the patients, the 
utilities were used in the model for all three interventions. 
B.4. Cost effectiveness 
Cost effectiveness of interventions was assessed by obtaining the incremental cost-
effectiveness ration (ICER). ICER was calculated by taking the difference between the mean 
values of the cost of interventions over the difference between the mean values of the QALYs 
gained of interventions; as: 
𝐼𝐶𝐸𝑅 =  
𝐶𝑜𝑠𝑡𝐷+𝑃̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅ − 𝐶𝑜𝑠𝑡𝑀+𝑃̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅
𝑄𝐴𝐿𝑌𝐷+𝑃̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ − 𝑄𝐴𝐿𝑌𝑀+𝑃̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅
 
where 𝐶𝑜𝑠𝑡𝐷+𝑃̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅ and 𝐶𝑜𝑠𝑡𝑀+𝑃̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅  defines the mean cost of D+P and M+P respectively and 
𝑄𝐴𝐿𝑌𝐷+𝑃̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅  and 𝑄𝐴𝐿𝑌𝑀+𝑃̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅   defines the mean QALY gained per patient for D+P and M+P 
respectively. 
Appendix C: Additional results 
C.1 Re-constructed IPD summary statistics 
Tables A1 and A2 show HRs for OS and PFS respectively, for all seven studies listed in Table A1 for completeness.  
 
Table C1:Individual trial’s HRs on OS obtained using IPD reconstructed from Kaplan-Meier survival curves 
Trial Comparison 
HR (95% CI)  
reported in journal article 
HR (95% CI)  
reported in HTA report 
HR (95% CrI)  
from reconstructed IPD 
     
Overall Survival 
    
TAX 327 D+P / M+P 0.76 (0.62-0.94) 0.76 (0.62-0.94) 0.76 (0.620, 0.936)      
CALGB 9182 M+H / H Not reported but median survival reported as: 
M+H 12.3 months and; 
H 12.6 months (p=0.77) 
1.05 (0.74, 1.49) 0.96 (0.732, 1.251) 
     
CCI-NOV 22 M+P / P Not reported but a total of 140 deaths  
reported at time of analysis (p=0.27) 
0.91 (0.69, 1.19) 0.81 (0.590, 1.110) 
     
Berry M+P / P Not reported but median survival reported as: 
M+P 23 months and; 
P 19 months (p=0.569) 
1.13 ( 0.75, 1.70) 0.95 (0.628, 1.432) 
     
     
Ernst M+P+Cl/M+P 1.05 (0.78, 1.42) 1.05 (0.78, 1.42) 1.08 (0.799, 1.452)      
SWOG D+E / M+P 0.8 (0.67, 0.97) 0.8 (0.67, 0.97) 0.79 (0.659, 0.955)      
Oudard D70+E+P / M+P Not reported but median survival reported as: 
D70+E+P 18.6 months, 
D35+E+P 18.4 months and; 
M+P 13.4 months 
0.94 (0.29, 1.02) 1.08 (0.675, 1.715) 
 
D35+E+P / M+P 0.86 (0.68, 1.08) 0.75 (0.448, 1.245) 
          
 
 Table C2: Individual trial’s HRs on PFS obtained using IPD reconstructed from Kaplan-Meier survival curves 
Trial Comparison 
HR (95% CI)  
reported in journal article 
HR (95% CI)  
reported in HTA report 
HR (95% CrI)  
from reconstructed IPD 
     
Progression-free Survival    
TAX 327 D+P / M+P Endpoint not collected Not possible Not possible      
CALGB 9182 M+H / H Not reported but median survival reported as: 
M+H 3.7 months and; 
H 2.3 months (p=0.0218) 
Time to progression 
(calculated from number of events and 
p-value 
presented in the trial publication)  
HR= 1.50 (1.06, 2.13); p = 0.0218 
0.74 (0.574, 0.954) 
     
CCI-NOV 22* M+P / P Not reported 0.47 (0.32, 0.68) Not possible+      
Berry* M+P / P Not reported but median survival reported as: 
M+P 8.1 months and; 
P 4.1 months (p=0.018) 
Estimated from the Kaplan-Meier 
curve for PFS presented in 
the trial publication. HR= 0.64 (0.48, 
0.86) 
0.63 (0.432, 0.927) 
     
Ernst M+P+Cl/M+P 0.81 (0.61, 1.07) 0.81 (0.61, 1.07) 0.84 (0.63, 1.112)      
SWOG D+E / M+P Not reported but median survival reported as: 
D+E 6.3 months and; 
M+P 3.2 months (p<0.001) 
time to disease progression observed  
for the docetaxel group compared  
with the mitoxantrone group:  
HR=1.30 (1.11, 1.52); p < 0.001 
0.73 (0.627, 0.860) 
     
Oudard* D70+E+P / M+P Not reported but median survival for time to 
PSA progression is reported as: 
D70+E+P 8.8 months, 
D35+E+P 9.3 months and; 
M+P 1.7 months 
Not reported Not possible  
D735+E+P / M+P Not reported Not possible 
     
*Trials where TTP was reported in the journal article or HTA report instead of PFS 
+No Kaplan-Meier survival curve in published article 
C.2 Justification for choice of Trial SWOG 
Overall survival curves for four RCTs in HTA Full Set (excluding CALGB 9182 which used 
hydrocortisone instead of prednisone and CCI-NOV22 which did not report PFS) were 
compared to the OS curve of trial TAX 327 and presented in Figure. The OS Kaplan-Meier 
curves suggested that trial SWOG has an OS profile closest to trial TAX 327. 
 
 
Figure C1: Overall survival Kaplan-Meier curves for RCTs in the HTA report  
 
Mean time to progression for patients administrated M+P for the four RCTs were estimated 
using the IPD reconstructed from PFS Kaplan-Meier curves. As described in Section 2.3.1, 
as PFS was not recorded in trial TAX 327, mean number of cycles of M+P administrated in 
trial TAX 327 was used for comparing with the mean time to progression in the four RCTs. 
The mean time to progression for the four RCTs and the mean number of cycles of M+P 
administrated in trial TAX 327 are shown in Table. Trials Ernst and SWOG have mean time 
to progression closest to the assumed mean time to progression of TAX 327. The results 
suggested that trial SWOG has an OS profile closest to trial TAX 327 and therefore 
potentially a PFS profile closest to TAX 327 if the PFS endpoint had been recorded. Hence, 
reconstructed IPD of trial SWOG were used to estimate the transition probabilities from StD 
state to PD state for M+P. 
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Table C3: Mean time to progression for RCTs in the HTA report 
Trial Mean Time to Progression (SE) 
  
Berry et al. 12.8 (1.63) 
Ernst 5.9 (0.53) 
SWOG 5.9 (0.33) 
Oudard 4.2 (0.88) 
  
 Mean no.of cycles (SE) 
TAX 327 5.9 (0.17) 
    
 
C.3 Cost and utility 
Costs of drug for interventions M+P and D+P were estimated using the mean cycle of 
chemotherapy administrated. The reported mean number of cycles for the interventions M+P 
and D+P were 5.9 (SE=0.17) and 7.3 (SE=0.18) respectively, Normal distributions were 
assigned to the number of treatment cycles to incorporate uncertainty around these values in 
the two economic models. Cost of drug for M+P was £347.73/cycle and £1253.92/cycle for 
D+P, including £177.46/cycle for outpatient attendance fees for both drug regimens. Cost of 
drug for P was calculated at £1.48 per patient per cycle. In the WinBUGS two-state model, the 
drug costs for a patient taking P was calculated for the number of cycles that the patient 
remains in the StD state before transition to the death state. In the three-state model, the cost 
drug for a patient taking P was calculated for the number of cycles that the patient remains in 
the StD state before transition to the PD state. It was assumed that the patient would stop 
taking P after progression and hence, no drug cost would be calculated for the cycles post-
progression before transition to the death state. 
Follow-up and terminal care costs for interventions M+P and D+P were estimated from trial 
TAX 327 as reported in the HTA report (Table 36 and Table 37 in (Collins et al., 2007)). 
Uncertainties for the costs were applied in the two economic models using Gamma 
distributions. Follow-up and terminal care costs for drug P were not available and were 
estimated from the costs of intervention M+P from trial TAX 327. In order to estimate the costs 
for drug P, a cost ratio of drug P with reference to drug M+P was estimated using costing data 
of P and M+P from a review article (Bloomfield et al., 1998). The mean cost ratio estimated in 
the WinBUGS two-state model was 1.278 (95% CrI: 0.946 to 1.691) which suggested that the 
mean cost of P was higher than the mean cost of M+P. This cost ratio was calculated by 
assigning Gamma distributions [Gamma(α,β)] of Gamma(105, 276) and Gamma(81, 285) to 
the cost data of P and M+P respectively. The mean cost (drug, follow-up and terminal care) 
per patient at each state in the economic model for each of the interventions are presented in 
Table C4. 
Mean EQ-5D HRQoL for all patients in the 12 months prior to death was 0.538 (95% CI: 0.461 
to 0.615) as reported in the study by Sandblom and colleagues (Sandblom et al., 2004). Using 
this EQ-5D data, the utility for StD state in the WinBUGS two-state model was defined using 
a beta distribution with parameter values: Beta(21.1, 18.1). For the three-state model, the 
utility distribution, Beta(21.1, 18.1), for the StD in the WinBUGS two-state model was assigned 
as the utility distribution for the PD state. Two additional EQ-5D values as discussed in Section 
2.3.3 were extracted from the Sandblom study (Sandblom et al., 2004), they were the EQ-5D 
for patients who were still surviving at the time of analysis of the study, EQ-5D = 0.770 (95% 
CI: 0.755 to 0.785), and EQ-5D of patients who died of other non-prostate cancer related 
death, EQ-5D = 0.564 (95% CI: 0.497 to 0.631). These two utility data were defined in the 
economic model using the following beta distributions, Beta(581.3, 173.6) and Beta(29.1, 
22.5) respectively. Utility for the StD state was calculated based on the method described in 
Section 2.3.3. 
As the utilities defined were selected to reflect the general HRQoL of patients with advanced 
prostate cancer and were independent of the interventions administrated by the patients, the 
utilities were used in the model for all three interventions. Mean QALY per patient for each of 
the interventions in the economic models are presented in Table C4. 
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Table C4: Mean cost, mean QALY and mean time spent per patient at each state in the economic model’ 
Economic Model Drug 
Mean Cost (£) 
(95% CrI) Drug cost (£) 
Mean QALYs 
(95% CrI) 
Mean Time 
(95% CrI) 
      
WinBUGS two-state model      
Stable & Progression Disease State P (direct) 11772 (6127, 20280) 26 (23, 31) 0.809 (0.5590, 1.0760) 18.1 (15.54, 21.03) 
 P (indirect) 11772 (6128, 20290) 27 (22, 32) 0.812 (0.5476, 1.1100) 18.2 (14.68, 22.41) 
 M+P 11237 (6855, 17030) 2057 (427, 3679) 0.813 (0.5718, 1.0580) 18.2 (16.55, 19.93) 
 D+P 15862 (9066, 23020) 9152 (3261, 15050) 0.967 (0.6746, 1.2690) 21.9 (19.50, 24.58) 
            
      
WinBUGS three-state model      
Stable Disease State P (direct) NA 6 (1, 18) 0.276 (0.0614, 0.7646) 4.1 (0.68, 12.03) 
Progression Disease State P (direct) NA 
mean cycles = 4.12 
(SE:1.47) 0.573 (0.2667, 1.0080) 13.4 (6.63, 22.81) 
     0.849 (0.4389, 1.4400) 17.5 (9.32, 28.90) 
  10152 (5160.0, 17760.0)
#    
      
Stable Disease State M+P 371 (211.6, 589.9) 2047 (400, 3678) 0.377 (0.3330, 0.4247) 5.7 (5.05, 6.40) 
Progression Disease State M+P 3804 (2088.0, 6345.0) 
mean cycles = 5.34 
(SE:0.17) 0.512 (0.3596, 0.6674) 11.9 (10.78, 13.12) 
Terminal care M+P 3756 (1026.0, 8239.0)  0.889 (0.7200, 1.0600) 17.6 (16.32, 18.99) 
  9977 (5995.0, 15250.0)    
      
Stable Disease State D+P 373 (218.1, 578.7) 9164 (3268, 15000) 0.619 (0.4967, 0.7602) 9.6 (7.67, 11.93) 
Progression Disease State D+P 2474 (1370.0, 4009.0) 
mean cycles = 6.62 
(SE:0.26) 0.522 (0.3664, 0.6796) 12.3 (11.15, 13.55) 
Terminal care D+P 3326 (916.2, 7266.0)  1.141 (0.9369, 1.3520) 22.0 (19.75, 24.40) 
  15337 (8594.9, 22440.0)    
            
#Calculated using mean cost ratio of 1.278 (95% CrI: 0.946 to 1.691) for P compared to M+P 
 
 
 
